Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

United Therapeutics (UTHR) Short-Term Debt repayments (2019 - 2025)

United Therapeutics' Short-Term Debt repayments history spans 7 years, with the latest figure at $400.0 million for Q2 2025.

On a quarterly basis, Short-Term Debt repayments rose 300.0% to $400.0 million in Q2 2025 year-over-year; TTM through Dec 2025 was $500.0 million, a 25.0% increase, with the full-year FY2025 number at $500.0 million, up 25.0% from a year prior.
Short-Term Debt repayments hit $400.0 million in Q2 2025 for United Therapeutics, up from $100.0 million in the prior quarter.
Over the last five years, Short-Term Debt repayments for UTHR hit a ceiling of $800.0 million in Q1 2022 and a floor of $100.0 million in Q4 2023.
Historically, Short-Term Debt repayments has averaged $225.0 million across 4 years, with a median of $100.0 million in 2023.
Biggest five-year swings in Short-Term Debt repayments: changed 0.0% in 2024 and later soared 300.0% in 2025.
Tracing UTHR's Short-Term Debt repayments over 4 years: stood at $800.0 million in 2022, then tumbled by 87.5% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024, then soared by 300.0% to $400.0 million in 2025.
Business Quant data shows Short-Term Debt repayments for UTHR at $400.0 million in Q2 2025, $100.0 million in Q1 2025, and $100.0 million in Q4 2024.